Clin Exp Vaccine Res.
2021 Sep;10(3):203-210. 10.7774/cevr.2021.10.3.203.
Parenteral, non-live rotavirus vaccine: recent history and future perspective
- Affiliations
-
- 1School of Biopharmaceutical and Medical Sciences, Sungshin Women’s University, Seoul, Korea
- KMID: 2525814
- DOI: http://doi.org/10.7774/cevr.2021.10.3.203
Abstract
- Since the widespread introduction of oral and live attenuated rotavirus vaccines around the world in 2009, the impacts of disease burden and the effects of disease reduction in developing countries have been proven. However, in low and middle-income countries, the vaccine efficacy is somewhat lower than in developed countries due to differences in nutritional conditions, microbial environments of individuals, and other factors. In addition, as oral, live vaccines have been found to be associated with rare but serious side effects, the development of a next-generation vaccine with safety, improved effectiveness, and ease of storage is currently underway. New vaccine strain developed by the Centers for Disease Control and Prevention in the United States are undergoing preclinical testing of efficacy, antigen dose, and administration route in the form of a heat-treated inactive vaccine, and a recombinant protein-based trivalent subunit vaccine developed by the Program for Appropriate Technology in Health is undergoing clinical trial in phase III. Several research groups are also developing non-replicating protein-based rotavirus vaccines using virus-like particles and nanoparticles. This review provides a brief overview of the development status and technology of parenteral, non-live rotavirus vaccines worldwide.
